Zantac Injection Premixed

— THERAPEUTIC CATEGORIES —
  • Hyperacidity, GERD, and ulcers

Zantac Injection Premixed Generic Name & Formulations

General Description

Ranitidine (as HCl) 1mg/mL in sodium chloride 0.45%; IV infusion; preservative-free.

Pharmacological Class

H2 blocker.

How Supplied

Tabs, syrup—contact supplier; Inj single dose (2mL)—10; Multidose (6mL)—1; Premixed (50mL)—24

Manufacturer

Zantac Injection Premixed Indications

Indications

Hospitalized patients with pathological hypersecretory conditions, intractable duodenal ulcer. Short-term alternative to oral therapy.

Zantac Injection Premixed Dosage and Administration

Adult

For slow IV drip only. >16yrs: Intermittent infusion: 50mg every 6–8hrs (infuse over 15–20mins); usual max 400mg/day. Continuous IV infusion, or for Zollinger-Ellison: see full labeling. Renal impairment (CrCl<50mL/min): 50mg every 18–24hrs or more often if needed (intermittent only). Coincide a dose for end of hemodialysis.

Children

<1month: not recommended. ≥1month–16yrs: Treatment of duodenal ulcer: 2–4mg/kg per day in divided doses every 6–8hrs; max 50mg every 6–8hrs.

Zantac Injection Premixed Contraindications

Not Applicable

Zantac Injection Premixed Boxed Warnings

Not Applicable

Zantac Injection Premixed Warnings/Precautions

Warnings/Precautions

History of acute porphyria: not recommended. Renal impairment: reduce dose. Hepatic dysfunction. Discontinue if hepatic disorders occur. Monitor SGPT if on high-dose IV therapy for ≥5 days. Pregnancy (Cat.B). Nursing mothers.

Zantac Injection Premixed Pharmacokinetics

See Literature

Zantac Injection Premixed Interactions

Interactions

May increase triazolam, midazolam, glipizide, procainamide levels. May decrease ketoconazole, atazanavir, delaviridine, gefitnib levels. Monitor anticoagulants. May cause false (+) urine protein test with Multistix.

Zantac Injection Premixed Adverse Reactions

Adverse Reactions

Headache, GI disturbances, jaundice, hepatitis, rash; rare: CNS disturbances, arrhythmias, blurred vision, arthralgia, myalgia, inj site reactions, blood dyscrasias, anaphylaxis, angioneurotic edema, acute interstitial nephritis, bradycardia with rapid administration (IV); increased risk of pneumonia (see full labeling).

Zantac Injection Premixed Clinical Trials

See Literature

Zantac Injection Premixed Note

Not Applicable

Zantac Injection Premixed Patient Counseling

See Literature